araag2/HINT huggingface dataset:
Clinical trial NCT00551148 (phase 2, status: completed)
Conditions: primary insomnia
ICD codes: F51.01
Drugs: pd 0200390, pd 0200390, pd 0200390, pd 0200390
SMILES: C[C@H]1CC(CN)(CC(O)=O)C[C@@H]1C, C[C@H]1CC(CN)(CC(O)=O)C[C@@H]1C, C[C@H]1CC(CN)(CC(O)=O)C[C@@H]1C, C[C@H]1CC(CN)(CC(O)=O)C[C@@H]1C
Eligibility criteria:

        Inclusion Criteria:

        3 month history of Primary Insomnia (DSM-IV criteria)

        Self report sleep criteria for at least 3 nights per week in past month;

        sWASO (subjective wake after sleep onset) equal or greater than 60 mins

        sLSO (subjective latency to sleep onset) equal or greater than 45 minutes

        TST less than or equal to 6.5 hrs

        Maintain normal daytime-awake, nighttime-sleep schedule

        PSG sleep criteria of mean WASO equal or greater than 60 mins calculated on 2 PSG screening
        nights

        TST between 3 to 7 hrs on 2 PSG screening nights

        Mean LPS (latency to persistent sleep) equal or greater than 20 mins calculated on 2 PSG
        screening nights

        Exclusion Criteria:

        Comorbid psychiatric disease or disorders

        History or presence of breathing-related disorders

        Multivariable Apnea risk index (MAP) equal or greater than 0.5 at screening

        History or presence of medical or neurological condition interfering with sleep

        Current use of know psychotropic effect medications

        Excessive caffeine use

        Use of alcohol as a sleep aid or more than 2 standard drinks/day
Clinical trial NCT00531934 (phase 2, status: completed)
Conditions: non-small cell lung cancer
ICD codes: C78.00, C78.01, C78.02, D14.30, D14.31, D14.32, C34.2
Drugs: doxycline, erlotinib [tarceva]
SMILES: COCCOC1=CC2=C(C=C1OCCOC)C(NC1=CC(=CC=C1)C#C)=NC=N2
Eligibility criteria:

        Inclusion Criteria:

          -  adult patients, 18-75 years of age;

          -  confirmed non-small cell lung cancer;

          -  failure after first line chemotherapy for advanced disease, and scheduled for second
             line therapy with Tarceva.

        Exclusion Criteria:

          -  rash of any etiology at study entry;

          -  history of significant heart disease;

          -  any other malignancies (other than adequately treated squamous cell skin cancer, or in
             situ cancer of the cervix);

          -  history of allergic reactions to tetracyclines.
Clinical trial NCT01830556 (phase 2, status: unknown status)
Conditions: squamous cell carcinoma of the head and neck
ICD codes: C22.0, C4A.9, C7B.1, C4A.0, C4A.31, C4A.51, C4A.8
Drugs: cetuximab
SMILES: [H][C@]12SCC(COC(C)=O)=C(N1C(=O)[C@H]2NC(=O)C(=N/OC)\C1=CSC(N)=N1)C(O)=O
Eligibility criteria:

        Inclusion criteria

          -  >18 years

          -  Histologically or cytologically confirmed SCCHN, relapsed and/or metastatic

          -  Patient must have a life expectancy of at least 3 months allowing adequate follow-up
             toxicity evaluation.

          -  Clinical examination

          -  1 unidimensional lesion according to RECIST 1.1.

          -  PS WHO 0-1 at study entry

          -  Adequate hematological function defined as WBC ≥3 x 109/litre and platelets ≥100 x
             109/litre, ANC > 1.5 x 109/litre and Hb > 100 g/L

          -  Adequate liver function; bilirubin < 1.5 x UNL, ALAT or ASAT<3.0 UNL, alkaline
             phosphates < 2.5 UNL.

          -  Creatinine clearance > 50mL/min

          -  Written informed consent must be obtained according to the local Ethics committee.

        Exclusion Criteria:

          -  > 75 years

          -  Nasopharyngeal cancer and cancer of the paranasal sinuses

          -  Inability to follow the treatment and evaluation schedule

          -  Any other condition or therapy which in the investigator's opinion may pose a risk to
             the patient or interfere with the study objectives

          -  Pregnant or nursing females or male or female of child-bearing potential not using
             adequate methods of birth-control

          -  Patients with active infections or any other serious underlying medical condition,
             which would impair the ability of the patients to receive the protocol treatment

          -  Known hypersensitivity to any of the components of the treatment

          -  Legal incapacity

          -  Clinically significant cardiovascular disease, e.g. cardiac failure of New York Heart
             Association classes III-IV, uncontrolled coronary artery disease, cardiomyopathy,
             uncontrolled arrhythmia, uncontrolled hypertension, or history of myocardial
             infarction in the last 12 months.

          -  Patients with clinically relevant neuropathy

          -  Previously treated for relapsed or metastatic SCCHN except radiotherapy for previously
             treated relapse if terminated > 3 months before start of treatment.

          -  Previously treated with cetuximab, cisplatin/carboplatin, 5-FU or taxanes for locally
             advanced SCCHN within 3 months before study entry.
Clinical trial NCT00429026 (phase 2, status: terminated)
Conditions: renal cell cancer
ICD codes: C96.20, C96.29, D47.09
Drugs: fludarabine, melphalan, cyclophosphamide
SMILES: ClCCN(CCCl)P1(=O)NCCCO1, N[C@@H](CC1=CC=C(C=C1)N(CCCl)CCCl)C(O)=O, ClCCN(CCCl)P1(=O)NCCCO1
Reason stopped: 
    slow accrual, study terminated.
  
Eligibility criteria:

        Inclusion Criteria:

          1. For registration: Willing to undergo allogeneic transplantation.

          2. For registration: Age equal to or less than 65 years old.

          3. For registration: Metastatic RCC with predominant conventional cell type.

          4. For registration: Prior nephrectomy.

          5. For registration: Stage IV RCC. If patient has prior single brain metastasis treated
             with complete surgical resection or stereotactic radiation therapy, no recurrence or
             brain edema from the end of treatment for at least 6 months has to be shown by
             radiological imaging.

          6. For registration: Zubrod performance status < one.

          7. For registration: Potential related donor for allogeneic stem cell transplantation.

          8. For registration: At least one prior treatment for metastatic RCC. Radiation therapy
             or surgery is not counted as a treatment.

          9. For registration: Signed an informed consent.

         10. For transplantation: Zubrod performance status < one.

         11. For transplantation: An HLA-matched (defined as 6/6 matches) related donor.

         12. For transplantation: Failed at least one prior treatment for metastatic RCC. Radiation
             therapy or surgery is not counted as a treatment.

         13. For transplantation: Adequate major organ functions (see section 4.17-4.20).

         14. For transplantation: Signed an informed consent for allogeneic stem cell
             transplantation.

        Exclusion Criteria:

          1. For registration: Prior history of allogeneic stem cell transplantation.

          2. For registration: Histologic feature with predominant non-conventional cell type.

          3. For registration: Multiple brain metastasis.

          4. For registration: Life expectancy is severely limited by concomitant illness.

          5. For transplantation: Multiple brain metastasis.

          6. For transplantation: Life expectancy is severely limited by concomitant illness.

          7. For transplantation: Clinically significant active infections.

          8. For transplantation: HIV infection.

          9. For transplantation: Chronic active hepatitis

         10. For transplantation: Pregnant or lactating women.

         11. For transplantation: Has all three risk factors: high serum lactate dehydrogenase, low
             hemoglobin, high corrected serum calcium.
Clinical trial NCT00729222 (phase 2, status: completed)
Conditions: heart failure
ICD codes: I50.814, I09.81, I50.82, I50.89, I50.9, T86.22, I11.0
Drugs: comparator: placebo, rolofylline
SMILES: CN(C)C(=N)NC(N)=N, CCCN1C2=C(NC(=N2)C23C[C@@H]4CC2C[C@H](C3)C4)C(=O)N(CCC)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Patients with heart failure and renal impairment, currently using furosemide, with
             systolic blood pressure >95 mm Hg

        Exclusion Criteria:

          -  Patient has active infection, use of diuretic within 3 hours of screening visit, has
             acute tubular necrosis or severe pulmonary disease, any heart problems within the last
             two weeks
Clinical trial NCT00510510 (phase 2, status: completed)
Conditions: chronic obstructive pulmonary disease (copd)
ICD codes: G91.1, I42.1, N11.1, J05.0, G47.33, J44.9, N13.8
Drugs: nva237 100 µg, placebo, nva237 200 µg
SMILES: C[N+]1(C)CCC(C1)OC(=O)C(O)(C1CCCC1)C1=CC=CC=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, C[N+]1(C)CCC(C1)OC(=O)C(O)(C1CCCC1)C1=CC=CC=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Male or female adults aged 40 years or older

          -  Patients with moderate to severe COPD according to the GOLD Guidelines (2006)

          -  Patients who have smoking history of at least 10 pack years

          -  Patients with a post-bronchodilator Forced Expiratory Volume in One Second (FEV1)
             equal or greater than 30% of the predicted normal value and less than 80% of the
             predicted normal value, and post-bronchodilator FEV1/FVC less than 0.7 at visit 2

          -  Written informed consent by the patient prior to initiation of any study-related
             procedure

        Exclusion Criteria:

          -  Patients requiring oxygen therapy on a daily basis for chronic hypoxemia, or who have
             been hospitalized for an exacerbation of their airways disease in the 6 weeks prior to
             visit 1 or during the screening period (up to visit 3).

          -  Patients who have had a respiratory tract infection within 6 weeks prior to visit 1 or
             during the screening period (up to visit 3).

          -  Patients with a history of asthma indicated by (but not limited to):

        Blood eosinophil count > 400/mm3, onset of symptoms prior to age 40 years.

          -  Patients with a history of long QT syndrome or whose QTc measured at visit 1 is
             prolonged (more than 440 ms for males or more than 460 ms for females).

          -  Patients with a history of untoward reactions to sympathomimetic amines or inhaled
             medication or any component thereof.

          -  Patients who, in the judgment of the investigator have a clinically relevant
             laboratory abnormality or a clinically significant condition such as (but not limited
             to) unstable ischemic heart disease, left ventricular failure, long term prednisone
             therapy, history of myocardial infarction, arrhythmia, narrow-angle glaucoma,
             symptomatic prostatic hyperplasia, bladder-neck obstruction or moderate to severe
             renal impairment that might compromise patient safety or compliance, interfere with
             evaluation, or preclude completion of the study.

          -  History of malignancy of any organ system, treated or untreated, within the past 5
             years whether or not there is evidence of local recurrence or metastases, with the
             exception of localized basal cell carcinoma of the skin.

        Other protocol-defined inclusion/exclusion criteria may apply
Clinical trial NCT00080951 (phase 2, status: completed)
Conditions: colorectal cancer
ICD codes: C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, C17.2
Drugs: fluorouracil, irinotecan hydrochloride, leucovorin calcium, oxaliplatin
SMILES: [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, CCC1=C2CN3C(=CC4=C(COC(=O)[C@]4(O)CC)C3=O)C2=NC2=CC=C(OC(=O)N3CCC(CC3)N3CCCCC3)C=C12, NC1=NC(=O)C2=C(NC[C@H](CNC3=CC=C(C=C3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)N2C=O)N1, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1
Eligibility criteria:

        DISEASE CHARACTERISTICS:

          -  Diagnosis of colorectal adenocarcinoma

               -  Metastatic disease

          -  Not curable by surgery or amenable to radiotherapy with curative intent

          -  Measurable disease

               -  Patients with only lesions measuring ≥ 1 cm but < 2 cm must use spiral CT scan
                  for pre- and post-treatment tumor assessments

          -  No known CNS metastases or carcinomatous meningitis

        PATIENT CHARACTERISTICS:

        Age

          -  18 and over

        Performance status

          -  ECOG 0-2

        Life expectancy

          -  At least 12 weeks

        Hematopoietic

          -  Absolute neutrophil count ≥ 1,500/mm^3

          -  Platelet count ≥ 100,000/mm^3

        Hepatic

          -  AST ≤ 5 times upper limit of normal (ULN)

          -  Bilirubin ≤ 0.5 mg/dL above ULN

        Renal

          -  Creatinine ≤ 1.5 times ULN OR

          -  Creatinine clearance ≥ 60 mL/min

        Cardiovascular

          -  No unstable angina

          -  No symptomatic congestive heart failure

          -  No serious uncontrolled cardiac arrhythmia

        Pulmonary

          -  No prior clinical diagnosis of interstitial lung disease

        Other

          -  Not pregnant or nursing

          -  Negative pregnancy test

          -  Fertile patients must use effective contraception

          -  No active or uncontrolled infection

          -  No other concurrent serious illness

          -  No pre-existing paraesthesias/dysesthesias of ≥ grade 2 that would interfere with
             function

          -  No other malignancy within the past 5 years except adequately treated basal cell or
             squamous cell skin cancer or adequately treated noninvasive carcinomas

        PRIOR CONCURRENT THERAPY:

        Biologic therapy

          -  No concurrent sargramostim (GM-CSF)

        Chemotherapy

          -  At least 6 months since prior adjuvant chemotherapy

          -  No prior fluorouracil for advanced colorectal cancer

          -  No prior adjuvant oxaliplatin

          -  No prior adjuvant irinotecan

        Endocrine therapy

          -  Not specified

        Radiotherapy

          -  No prior radiotherapy to > 25% of bone marrow

        Surgery

          -  At least 4 weeks since prior major surgery
Clinical trial NCT00258297 (phase 2, status: terminated)
Conditions: esophageal cancer
ICD codes: K22.2, K22.81, Q39.4, P78.83, I85.00, I85.01, I85.10
Drugs: gefitinib
SMILES: COC1=C(OCCCN2CCOCC2)C=C2C(NC3=CC(Cl)=C(F)C=C3)=NC=NC2=C1
Reason stopped: 
    withdrawn for lack of funding and accrual
  
Eligibility criteria:

        DISEASE CHARACTERISTICS:

          -  Histologically confirmed squamous cell or adenocarcinoma of the thoracic esophagus

               -  Resectable, localized disease with or without metastases in local lymph nodes
                  (T1, T2, or T3; any N; M0)

               -  Stage I-III disease

          -  No known distant metastases

          -  No cervical-esophageal tumors (upper border < 18 cm from the incisor teeth)

          -  No supraclavicular metastases

        PATIENT CHARACTERISTICS:

        Performance status

          -  ECOG 0-2

        Life expectancy

          -  Not specified

        Hematopoietic

          -  Adequate bone marrow function

        Hepatic

          -  Adequate hepatic function

          -  No unstable or uncompensated hepatic disease

        Renal

          -  Creatinine ≤ grade 2 by Common Toxicity Criteria

          -  Adequate renal function

          -  No unstable or uncompensated renal disease

        Cardiovascular

          -  No unstable or uncompensated cardiac disease

        Pulmonary

          -  No clinically active interstitial lung disease unless it is asymptomatic with chronic
             stable radiographic changes

          -  No unstable or uncompensated respiratory disease

        Other

          -  Not pregnant or nursing

          -  Fertile patients must use effective contraception

          -  No known hypersensitivity to gefitinib or any of the excipients

          -  No other malignancy within the past 2 years except basal cell carcinoma or carcinoma
             in situ of the cervix

          -  No evidence of severe or uncontrolled systemic disease

          -  No other significant clinical disorder or laboratory finding that would preclude study
             participation

        PRIOR CONCURRENT THERAPY:

        Endocrine therapy

          -  Concurrent stable-dose steroids allowed

        Surgery

          -  Recovered from any prior oncologic or other major surgery

        Other

          -  More than 30 days since prior nonapproved or investigational drug

          -  No prior therapy for this or any other malignancy

          -  No concurrent phenytoin, carbamazepine, barbiturates, rifampin, or Hypericum
             perforatum (St. John's wort)
Clinical trial NCT01388933 (phase 2, status: terminated)
Conditions: crohn's disease
ICD codes: K50.90, K50.913, K50.914, K50.911, K50.912, K50.918, K50.919
Drugs: tu-100, matching placebo
SMILES: CN1C2C3=C(C1C1=CC=CC=C1C2=O)C(=O)C1=CC=CC=C1C3=O, CC1=CC(O)=CC(C)=C1Cl
Reason stopped: 
    study stopped due to low enrollment
  
Eligibility criteria:

        Inclusion Criteria:

          -  provide written informed consent

          -  ability to orally ingest study medication

          -  male or female between 18 to 75 inclusive

          -  diagnosed with Crohn's disease for at least 3 months

          -  CDAI score of 220-300 at screening

          -  sexually active participants of childbearing potential must agree to birth control

          -  no clinically significant conditions which the doctor would feel exclusionary

          -  stable medication (including probiotics)

        Exclusion Criteria:

          -  history of any bowel condition that may interfere with the evaluation of the study
             drug

          -  positive stool cultures

          -  currently pregnant or lactating

          -  receiving total parenteral nutrition

          -  history of alcohol or drug abuse within one year

          -  history of malignancy within 5 years

          -  current use of anticholinergic agents, antidepressants during the study, warfarin,
             prokinetics, antipsychotic agents or narcotic analgesics

          -  treatment with Anti-TNF agents 12 weeks before screening

          -  treatment with corticosteroids four weeks prior to screening

          -  treatment with cyclosporine or tacrolimus eight weeks prior to screening

          -  presence of a poorly controlled medical condition

          -  history of allergic reaction to ginseng, ginger or sichuan pepper

          -  any use of supplemental ginger, ginseng and Sichuan powder 2 weeks prior to and
             through course of the trial

          -  current use of any of the following herbal medications: Boswellia, Cat's claw (Uncaria
             tomentosa), Cayenne pepper, Echinacea, Horsetail (Equisetum), Hops, Lady's mantle
             (Alchemilla), Marshmallow root (Althaea), Slippery elm (Ulmus rubra) Turmeric and
             White Willow (Salix alba)

          -  history of celiac disease

          -  current diagnosis of lactose intolerance

          -  history of any other investigational medication within 30 days of enrolling in study

          -  unsuitability as determined by the study doctor
Clinical trial NCT01227434 (phase 2, status: terminated)
Conditions: glioblastoma, gliosarcoma, anaplastic astrocytoma
ICD codes: C84.67, C84.77, C84.7A, C84.60, C84.70, C84.62, C84.66
Drugs: pd 0332991 (pre-surgery), pd 0332991
SMILES: CC(=O)C1=C(C)C2=CN=C(NC3=NC=C(C=C3)N3CCNCC3)N=C2N(C2CCCC2)C1=O, CC(=O)C1=C(C)C2=CN=C(NC3=NC=C(C=C3)N3CCNCC3)N=C2N(C2CCCC2)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Patients 18 years or older with KPS > 60, with life expectancy of > 8 weeks with
             radiographically proven recurrent, intracranial Glioblastoma multiforme or
             Gliosarcoma; patients must have documentation of Rb positive disease.

          -  All patients must sign an informed consent and must have signed an authorization for
             the release of their protected health information.

          -  Patients must have had prior external beam radiation and temozolomide chemotherapy;
             there is no limit to the number of prior chemotherapies used; patients may be treated
             in their first, second or third relapse

          -  Patients must have recovered from the toxic effects of prior therapy

          -  Patients must have adequate bone marrow function and renal function before starting
             therapy. A pre-study EKG with a normal QT interval is required for all patients

          -  Patients must have shown unequivocal evidence for tumor progression by MRI scan and on
             a steroid dose that has been stable for at least 7 days.

          -  Patients must have an interval of greater than or equal to 42 days from the completion
             of radiation therapy to study entry.

          -  A subset of 15 patients will be enrolled prior to a planned, indicated surgical
             resection. Patients can be enrolled pre-operatively only if they are surgical
             candidates, do not have evidence of an acute intracranial hemorrhage and are able to
             start protocol treatment in a window of 7 days before surgery.

          -  Male and female patients with reproductive potential must use an approved
             contraceptive method. Women of childbearing potential must have a negative beta-HCG
             pregnancy test

          -  Blocks or slides of tumor tissue from a previous surgery must be available to do IHC
             Rb staining. Patients with negative tumors (Rb negative) will be excluded from the
             study.

        Exclusion Criteria:

          -  Patients must not have any significant medical illnesses that in the investigator's
             opinion cannot be adequately controlled with appropriate therapy or would compromise
             the patient's ability to tolerate this therapy.

          -  Patients with a history of any other cancer (except non-melanoma skin cancer or
             carcinoma in-situ of the cervix), unless in complete remission and off of all therapy
             for that disease for a minimum of 3 years are ineligible.

          -  Patients on enzyme-inducing anti-epileptic drugs or other drugs that cause CYP3A
             enzyme induction or inhibition will not be eligible